ClinicalTrials.Veeva

Menu

rTMS for Aneroxia Nervosa in Youth (MULTI-REX)

University of California, Los Angeles (UCLA) logo

University of California, Los Angeles (UCLA)

Status

Not yet enrolling

Conditions

Anorexia Nervosa

Treatments

Device: Transcranial Magnetic Treatment

Study type

Interventional

Funder types

Other

Identifiers

NCT04846517
20-001905

Details and patient eligibility

About

This study will examine the feasibility of off-label multilocus repetitive transcranial magnetic stimulation (rTMS) for symptoms of Anorexia Nervosa in participants between the ages of 14-24. rTMS is a non-invasive, brain-based intervention that uses magnets to deliver energy to the brain. The investigators will also see if patients receiving multilocus rTMS show any improvements in their eating disorder, mood, anxiety, and obsessions and compulsions (if present). Participants will receive daily intervention with off-label multilocus rTMS for 20 total treatments. Participants will also be asked to complete mental health and well-being surveys, physical measurements, and 2 brain imagining scans (MRIs) at baseline, and at study end. The investigators will also ask participants to complete surveys are 1-month and 3-months after the final rTMS session. The target enrollment for this study is 45 participants.

Enrollment

45 estimated patients

Sex

All

Ages

14 to 24 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. youth aged 14-24 with DSM-5 AN-restricting (ANR) or AN-binge-eating-purging (ANBP) type as determined by the MINI-KID/MINI and clinical interview;
  2. YBC-EDS score≥16,
  3. baseline CGI-S score ≥4,
  4. English speaking (as this complement of questionnaires are available in English)
  5. on stable psychotropic medication (if any) for the preceding 4 weeks (i.e., SSRIs, atypical antipsychotics and benzodiazepines of doses <1 mg lorazepam equivalent daily),
  6. medically stable, as determined by their treating clinician, and
  7. not deemed to be at high risk of imminent suicidal behavior by initial study psychiatrist assessment and referring provider/team, and no endorsement of items 4 or 5 on the Severity of Ideation Subscale of the C-SSRS.
  8. For women: not currently pregnant and on reliable birth control if sexually active (as the effects of rTMS on the unborn fetus are unknown).

Exclusion criteria

  1. a lifetime history of psychosis, mania, or seizure disorder
  2. active suicidality as determined by clinical assessment by MD or PhD, and endorsement of items 4 or 5 on the Severity of Ideation Subscale of the C-SSRS.
  3. unstable neurological disorder,
  4. metal in head/eye,
  5. inability to tolerate MRI,
  6. at high risk of alcohol withdrawal or substance intoxication,
  7. diagnosis of pervasive development disorder,
  8. medical instability as determined by primary care provider and/or referring clinician (i.e., unstable electrolytes in the setting of worsening binge-eating/purging, cardiac arrhythmias requiring Holter or other intensive monitoring),
  9. For women: pregnant or not using a reliable form of birth control.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

45 participants in 1 patient group

TMS Treatment
Other group
Description:
iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC LF-rTMS treatment: Delivered immediately after iTBS treatment as described above. SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA
Treatment:
Device: Transcranial Magnetic Treatment

Trial contacts and locations

0

Loading...

Central trial contact

Jonathan Lee, MD; Doan Ngo, BS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems